Drugs show promise for childhood brain tumors, ovarian cancer

An experimental drug has shown promise in treating malignant brain tumors in children, a small study unveiled at the annual American Society of Clinical Oncology conference showed Sunday.

The early stage trial tested the effects of GDC-0449 on drug-resistant medulloblastomas, the most common form of brain tumor found in children.

Developed by US biotech firms Curis and Genentec, the latter owned by Swiss pharmaceutical group Roche since 2009, the drug works by blocking the so-called "Hedgehog" pathway.

The pathway is key to regulating cell growth and is implicated in around 20 percent of medulloblastomas, as well as other cancers.

The trial involved just 13 children, 12 of whom tolerated the drug without any significant side effects. One of the children in the trial went a year on the drug without any tumor progression.

In a previous case, a young adult with medulloblastoma experienced a similarly positive result, according to Amar Gajjar, director of the Neuro-Oncology Division at St. Jude's Children's Research Hospital in Tennessee and lead investigator in the research.

"Some patients have remained on this trial for extended periods of time, and our early results are positive and encouraging," he said at a press conference during the annual meeting of cancer researchers.

"The trend in treating children with these cancers is toward targeted therapies like this one, which block key signaling pathways and disable the cancer's ability to function or reproduce," he added.

Another study presented Sunday showed new ways to slow the return of certain types of ovarian cancer in women who have undergone chemotherapy.

The research analyzed the effect of giving a drug called Avastin to women suffering from advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

The drug, known generically as bevacizumab, works by blocking the development of blood vessels that can promote tumor growth.

"This is the first time a Phase III trial has demonstrated that an anti-angiogenic agent improved progression-free survival in women with this very hard-to-treat-disease," said Robert Burger of the Fox Chase Cancer Center in Philadelphia, who led the research.

"Based on the results of this... trial, bevacizumab is an acceptable initial treatment option for patients with advanced ovarian, primary peritoneal and fallopian tube cancers," said Burger.

Avastin is sold by US firm Genetech, part of Swiss pharmaceutical group Roche and has already been authorized by the US Food and Drug Administration for use in treating cancers including colon, breast, kidney, brain and lung.

Previous small-scale clinical studies involving Avastin had shown the drug's potential for ovarian cancer patients, but this trial involved an international pool of 1,873 women with newly-diagnosed advanced stage ovarian, primary peritoneal or fallopian tube cancer.

The women had all undergone surgery to remove as much of the tumor as possible, and were assigned to one of three groups.

The first received standard chemotherapy supplemented with a placebo and then received a placebo for follow-up medicine; the second received chemotherapy plus Avastin and a placebo follow-up drug; the third received chemotherapy plus Avastin and also took Avastin to follow-up.

Those in the final group had a median recurrence-free survival rate of 14.1 months, compared with the 10.3 month rate among those who received chemotherapy alone - a statistically significant difference.

The difference between the third group and those who only took Avastin during chemotherapy was judged statistically insignificant.

Ovarian cancer affects some 230,000 women each year, killing around 140,000. It is the eighth most deadly cancer among women.

Life and Style
ebookNow available in paperback
ebookPart of The Independent’s new eBook series The Great Composers
Life and Style
A picture taken on February 11, 2014 at people walking at sunrise on the Trocadero Esplanade, also known as the Parvis des droits de l'homme (Parvis of Human Rights), in front of the Eiffel Tower in Paris.
techGoogle celebrates Paris's iconic landmark, which opened to the public 126 years ago today
Scientists believe Mercury is coated in billions of years’ worth of carbon dust, after being ‘dumped on’ by passing comets
Cleopatra the tortoise suffers from a painful disease that causes her shell to disintegrate; her new prosthetic one has been custom-made for her using 3D printing technology
newsCleopatra had been suffering from 'pyramiding'
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: IT Software Developer / Programmer

    £20000 - £30000 per annum: Recruitment Genius: IT Software Developer / Program...

    Recruitment Genius: Business Development Executives

    £16000 - £18000 per annum: Recruitment Genius: As one of Europe's leading prov...

    Sheridan Maine: Accounts Assistant

    £30,000 Annual: Sheridan Maine: A fantastic opportunity has arisen for a perso...

    Sheridan Maine: Accounts Payable Clerk

    £21,000 - £24,000 Annual: Sheridan Maine: Are you looking for a new opportunit...

    Day In a Page

    No postcode? No vote

    Floating voters

    How living on a houseboat meant I didn't officially 'exist'
    Louis Theroux's affable Englishman routine begins to wear thin

    By Reason of Insanity

    Louis Theroux's affable Englishman routine begins to wear thin
    Power dressing is back – but no shoulderpads!

    Power dressing is back

    But banish all thoughts of Eighties shoulderpads
    Spanish stone-age cave paintings 'under threat' after being re-opened to the public

    Spanish stone-age cave paintings in Altamira 'under threat'

    Caves were re-opened to the public
    'I was the bookies’ favourite to be first to leave the Cabinet'

    Vince Cable interview

    'I was the bookies’ favourite to be first to leave the Cabinet'
    Election 2015: How many of the Government's coalition agreement promises have been kept?

    Promises, promises

    But how many coalition agreement pledges have been kept?
    The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

    The death of a Gaza fisherman

    He built his own reef, and was fatally shot there by an Israeli gunboat
    Saudi Arabia's airstrikes in Yemen are fuelling the Gulf's fire

    Saudi airstrikes are fuelling the Gulf's fire

    Arab intervention in Yemen risks entrenching Sunni-Shia divide and handing a victory to Isis, says Patrick Cockburn
    Zayn Malik's departure from One Direction shows the perils of fame in the age of social media

    The only direction Zayn could go

    We wince at the anguish of One Direction's fans, but Malik's departure shows the perils of fame in the age of social media
    Young Magician of the Year 2015: Meet the schoolgirl from Newcastle who has her heart set on being the competition's first female winner

    Spells like teen spirit

    A 16-year-old from Newcastle has set her heart on being the first female to win Young Magician of the Year. Jonathan Owen meets her
    Jonathan Anderson: If fashion is a cycle, this young man knows just how to ride it

    If fashion is a cycle, this young man knows just how to ride it

    British designer Jonathan Anderson is putting his stamp on venerable house Loewe
    Number plates scheme could provide a licence to offend in the land of the free

    Licence to offend in the land of the free

    Cash-strapped states have hit on a way of making money out of drivers that may be in collision with the First Amendment, says Rupert Cornwell
    From farm to fork: Meet the Cornish fishermen, vegetable-growers and butchers causing a stir in London's top restaurants

    From farm to fork in Cornwall

    One man is bringing together Cornwall's most accomplished growers, fishermen and butchers with London's best chefs to put the finest, freshest produce on the plates of some of the country’s best restaurants
    Robert Parker interview: The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes

    Robert Parker interview

    The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes
    Don't believe the stereotype - or should you?

    Don't believe the stereotype - or should you?

    We exaggerate regional traits and turn them into jokes - and those on the receiving end are in on it too, says DJ Taylor